口服免疫调节预防脊髓损伤患者原发性康复期间尿路感染的随机安慰剂对照预试验方案
该方案为单中心、随机、准盲法、安慰剂对照的预试验,纳入急性脊髓损伤(病程≤56天)且年龄18至70岁、接受原发性康复的患者,分两组每组12人,口服大肠埃希菌裂解物或安慰剂90天。主要评估主试验可行性、症状性尿路感染数量、尿液培养及蛋白组与微生物组、血细胞计数与不良事件。
要点
- 急性脊髓损伤康复期患者尿路感染常见,复发性抗生素治疗加剧细菌耐药问题。
- 口服大肠埃希菌裂解物安全性较好,但现有预防证据稀疏,需预试验评估可行性。
- 预试验若可行性结论积极,将开展更大规模、足够把握度的多中心试验验证效果。
核心结论
- 口服大肠埃希菌裂解物预防脊髓损伤后神经源性下尿路功能障碍患者尿路感染的证据目前稀疏,本预试验旨在评估后续主试验的可行性。
研究设计与样本
- 单中心、随机、准盲法、安慰剂对照预试验,设两个平行组,每组12名参与者。
- 纳入18至70岁、急性脊髓损伤(病程≤56天)并接受原发性康复的个体。
- 干预为口服冻干大肠埃希菌菌株裂解物(Uro-Vaxom®,OM Pharma SA),疗程90天;参与者不知治疗分配,护理人员按原包装准备每日剂量,试验人员与生物统计师设盲。
- 在干预开始前、干预结束时及干预终止后3个月采集血液和尿液样本。
关键数值与推荐
- 可行性指标包括招募率和患者脱落率;临床指标包括症状性尿路感染数量;实验室指标包括尿液培养、尿液蛋白组与微生物组、血细胞计数;同时收集不良事件。
局限性
- 原文未报告样本量计算依据、主要可行性阈值及统计分析方法等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Urinary tract infections (UTIs) are common in individuals with neurogenic lower urinary tract dysfunction (NLUTD) following spinal cord injury (SCI). They are not only a great burden for affected individuals, but also cause considerable health costs. Furthermore, recurrent antibiotic treatments of UTIs contribute to the growing problem of bacterial resistance to antimicrobial compounds. Even though there is a multitude of different measures to prevent UTIs in individuals with NLUTD, no clear evidence exists for any of these. Oral immunomodulation with UTI-relevant Escherichia coli lysate may be a promising preventative measure with a good safety profile in individuals with NLUTD. However, currently available data are sparse. METHODS: This is a randomized, quasi-blinded, placebo-controlled, mono-centric pilot trial investigating the feasibility of a main trial regarding the effects of a lyophilized lysate of E. coli strains for oral application (Uro-Vaxom®, OM Pharma SA, Meyrin, Switzerland). There will be two parallel groups of 12 participants each. Individuals with acute SCI (duration SCI ≤ 56 days) from 18 to 70 years of age admitted for primary rehabilitation will be eligible. Blood and urine samples will be taken prior to intervention start, at the end of the intervention, and 3 months after intervention termination. The trial intervention will last 90 days. The participants will not be informed regarding the treatment allocation (quasi-blinded). The nursing staff will prepare the daily dose of the allocated treatment from the original packaging. The trial personnel and the biostatistician will be blinded. Feasibility (e.g., recruitment rate, patient attrition), clinical (e.g., number of symptomatic UTIs), and laboratory parameters (e.g., urinary culture, urinary proteo- and microbiome, blood cell counts) as well as adverse events will be collected. DISCUSSION: Effective and efficient measures for the prevention of UTIs in individuals with NLUTD are urgently needed. If the conclusion of this pilot is positive regarding feasibility, the effects of oral immunomodulation with a E. coli lysate will be investigated in a larger, sufficiently powered, multi-center trial. TRIAL REGISTRATION: ClinicalTrials.gov NCT04049994 . Registered on 8 August 2019.
引用
- Krebs J, Stoyanov J, Wöllner J, et al. Immunomodulation for primary prevention of urinary tract infections in patients with spinal cord injury during primary rehabilitation: protocol for a randomized placebo-controlled pilot trial (UROVAXOM-pilot). Trials. 2021. PMID: 34607600. doi:10.1186/s13063-021-05630-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。